At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 376 enrolled
Drug / intervention
Canagliflozin (JNJ-28431754) +1 moredrug
Likely dose
Canagliflozin (JNJ-28431754) 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Investigate the Safety and Efficacy of JNJ-28431754 in Nondiabetic Overweight and Obese Subjects
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·interventional·Posted Apr 2, 2008·Updated May 24, 2013
In Brief
A Phase 2 clinical trial evaluating Canagliflozin (JNJ-28431754) and Placebo for Obesity. Completed, enrolled 376 participants across 36 sites in 2 countries.
Detailed Summary
The purpose of this study is to test the safety and effectiveness of JNJ-28431754 in promoting weight loss in patients who are overweight or obese and who do not have diabetes.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesPuerto Rico, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2008
Enrollment StartMay 2008
Primary CompletionSep 2008
TodayJul 2026
First PostedApr 2, 2008
Enrollment StartMay 1, 2008
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 18.3 years ago
Interventions
Canagliflozin (JNJ-28431754)drug
One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
Placebodrug
One matching placebo capsule orally once daily for 12 weeks.